

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣藥業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1681)

VOLUNTARY ANNOUNCEMENT SHARE REPURCHASE PROGRAM UNDER THE REPURCHASE MANDATE

This announcement is made by Consun Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders of the Company (the “**Shareholders**”) and potential investors about the latest business development of the Group.

In accordance with the general mandate granted by the Shareholders at the annual general meeting held on 22 May 2025, the board (the “**Board**”) of directors (the “**Directors**”) of the Company was granted to repurchase up to 85,126,334 shares of the Company (the “**Shares**”), representing 10% of the total number of Shares in issue as at 22 May 2025 (the “**Repurchase Mandate**”).

On 13 June 2025, the Board resolved to implement a share repurchase program to repurchase Shares in the open market as appropriate at the aggregate capital amount up to HKD200 million (the “**Previous Share Repurchase Program**”). On 29 January 2026, the Board resolved to further implement another share repurchase program under the Repurchase Mandate to repurchase Shares in the open market as appropriate, increasing up to a further HKD100 million in addition to the aggregate capital amount of the Previous Share Repurchase Program (the “**Share Repurchase Program**”). The aggregate capital amount proposed to be utilised accordingly under the Share Repurchase Program will not exceed HKD300 million. The period for the Share Repurchase Program is from the date of this announcement until the conclusion of the next annual general meeting of the Company or revocation or variation of the Repurchase Mandate by the Shareholders in the general meeting.

Under the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), the repurchase price of each Share shall not be more than 5% higher than the average closing market price for the Shares over the 5 trading days immediately preceding each repurchase.

The Board is confident in the business development and prospects of the Company and believes that the current share price of the Company does not adequately reflect its intrinsic value and long-term growth potential. The Board believes that, depending on the prevailing market conditions and financing arrangements, the Share Repurchase Program is consistent with the Company’s long-term development strategy. The implementation of the Share Repurchase Program will optimise the management of the Company’s capital structure and enhance the net asset value per Share and/or earnings per Share, which is in the interests of the Company and the Shareholders as a whole.

The Company maintains a solid financial position, and intends to finance the repurchase of Shares by its existing available cash while maintaining sufficient financial resources for the continued growth of its operations.

The Share Repurchase Program will be conducted pursuant to the Repurchase Mandate and in compliance with the memorandum of association and the articles of association of the Company, the Listing Rules, The Codes on Takeovers and Mergers and Share Buy-backs (the “**Takeovers Code**”) and all other applicable laws and regulations. The Company will subsequently cancel or hold in treasury the repurchased Shares under the Share Repurchase Program as deemed appropriate by the Board.

The Directors have no intention to exercise the Repurchase Mandate to the extent that would result in the number of Shares in the hands of the public falling below the prescribed minimum percentage as required by the Stock Exchange or give rise to an obligation to make a general offer to the Shareholders under Rules 26 and 32 of the Takeovers Code. Shareholders and potential investors of the Company should note that any repurchase of Shares made by the Company under the Share Repurchase Program will be subject to market conditions and will be at absolute discretion of the management of the Company. There is no assurance of the timing, quantity or price of any Share repurchase or whether or not the Company will make any Share repurchase.

Shareholders and potential investors of the Company are advised to exercise cautions when dealing in the Shares.

By Order of the Board
Consun Pharmaceutical Group Limited
AN Meng
Chairman

Hong Kong, 29 January 2026

As at the date of this announcement, the Board comprises Mr. An Meng and Mr. Young Yuk Chuen David as executive Directors; Dr. Zhang Lihua and Professor Zhu Quan as non-executive Directors; Mr. Feng Zhongshi, Professor Li Yikai, Mr. Li Zhuoguang and Mr. Duan Weiwu as independent non-executive Directors.